A Galapagos company

Abound Bio

Generating novel antibody-based biological therapeutics
Abound Bio is a US company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Galapagos acquired Abound Bio in 2022.

Pioneering for patients
with Galapagos

In 2022, Abound Bio was acquired by Galapagos. Since then, we have been united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life.

As a result, we will be sharing all company updates, news, and insights on Galapagos’ website.

Latest news

Stay in the know about our progress, and visit our Newsroom

Our stories

Read more about how we are #LivingInnovation in our stories

Investor hub

Looking for information about our company, our stock and our financials?